Abstract:Fungal infections affect millions of people globally and are often unreceptive to conventional topical or oral preparations because of low drug bioavailability at the infection site, lack of sustained therapeutic effect, and the development of drug resistance. Amphotericin B (AmB) is one of the most potent antifungal agents. It is increasingly important since fungal co-infections associated with COVID-19 are frequently reported. AmB is only administered via injections (IV) and restricted to life-threatening infections due to its nephrotoxicity and administration-related side effects. In this work, we introduce, for the first time, dissolving microneedle patches (DMP) loaded with micronised particles of AmB to achieve localised and long-acting intradermal delivery of AmB for treatment of cutaneous fungal infections. AmB was pulverised with poly (vinyl alcohol) and poly (vinyl pyrrolidone) to form micronised particles-loaded gels, which were then cast into DMP moulds to form the tips. The mean particle size of AmB in AmB DMP tips after pulverisation was 1.67 ± 0.01 μm. This is an easy way to fabricate and load microparticles into DMP, as few steps are required, and no organic solvents are needed. AmB had no covalent chemical interaction with the excipients, but the crystallinity of AmB was reduced in the tips. AmB was completely released from the tips within 4 days in vitro. AmB DMP presented inhibition of Candida albicans (CA) and the killing rate of AmB DMP against CA biofilm inside porcine skin reached 100% within 24 h. AmB DMP were able to pierce excised neonatal porcine skin at an insertion depth of 301.34 ± 46.86 μm. Ex vivo dermatokinetic and drug deposition studies showed that AmB was mainly deposited in the dermis. An in vivo dermatokinetic study revealed that the area under curve (AUC0-inf) values of AmB DMP and IV (Fungizone® bolus injection 1 mg/kg) groups were 8823.0 d∙μg/g and 33.4 d∙μg/g, respectively (264-fold higher). AmB remained at high levels (219.07 ± 102.81 μg/g or more) in the skin until 7 days after the application of AmB DMP. Pharmacokinetic and biodistribution studies showed that AmB concentration in plasma, kidney, liver, and spleen in the AmB DMP group was significantly lower than that in the IV group. Accordingly, this system addressed the systemic side effects of intravenous injection of AmB and localised the drug inside the skin for a week. This work establishes a novel, easy and effective method for long-acting and localised intradermal drug delivery.

Microemulsion Based Gel for Topical Dermal Delivery of Pseudolaric Acid B: in Vitro and in Vivo Evaluation

Preparation of Pseudolaric Acid B Microemulsion and Its Transdermal Penetration

Preparation and evaluation of dl-praeruptorin A microemulsion based hydrogel for dermal delivery.

Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: Potential for enhanced treatment of cutaneous fungal infections

Preparation and evaluation of<i>dl</i>-praeruptorin A microemulsion based hydrogel for dermal delivery

Development and evaluation of nanoemulsion gel loaded with bioactive extract of Cucumis melo var. agrestis: A novel approach for enhanced skin permeability and antifungal activity

Development and Evaluation of Azelaic Acid-Loaded Microemulsion for Transfollicular Drug Delivery Through Guinea Pig Skin: A Mechanistic Study

Quality by Design Guided Development of Polymeric Nanospheres of Terbinafine Hydrochloride for Topical Treatment of Onychomycosis Using a Nano-Gel Formulation

Percutaneous Delivery of Econazole Using Microemulsion As Vehicle: Formulation, Evaluation and Vesicle-Skin Interaction

Preparation, Characterization, and Evaluation of Amphotericin B-loaded MPEG-PCL-g-PEI Micelles for Local Treatment of Oral Candida Albicans

The preparation and in vivo disposition of skin-absorped liposomal gel including psoralen and dexamethasone acetate

Preparation and Evaluation of Azelaic Acid Topical Microemulsion Formulation: In Vitro and In Vivo Study

Microemulsions Based on Paeonol-Menthol Eutectic Mixture for Enhanced Transdermal Delivery: Formulation Development and in Vitro Evaluation

The Preparation and Evaluation of a Hydrochloride Hydrogel Patch with an Iontophoresis-Assisted Release of Terbinafine for Transdermal Delivery

Dual Roles of TPGS Based Microemulsion for Tacrolimus: Enhancing the Percutaneous Delivery and Anti-Psoriatic Efficacy.

Cationic Polymer-Based Micro-Emulgel with Self-Preserving Ability for Transdermal Delivery of Diclofenac Sodium

Pseudolaric Acid B Ameliorates Fungal Keratitis Progression by Suppressing Inflammation and Reducing Fungal Load

Potential of Non-aqueous Microemulsions to Improve the Delivery of Lipophilic Drugs to the Skin

Investigation of Microemulsion System for Transdermal Drug Delivery of Amphotericin B

Development and characterization of topical ethosomal gel for improved antifungal therapeutics

A poly-δ-decalactone (PDL) based nanoemulgel for topical delivery of ketoconazole and eugenol against Candida albicans